GET THE APP

..

Journal of Blood & Lymph

ISSN: 2165-7831

Open Access

Keisuke Teshigawara

Higashinotoin Clinic, Kyoto, Japan

Publications
  • Case Report   
    Efficacy and Future Prospects of ANK Therapy for ATL, Malignant Lymphoma and Solid Tumors
    Author(s): Kenjiro Nagai*, Syo Nagai, Yuji Okubo and Keisuke Teshigawara

    Amplified Natural Killer Cell (ANK) therapy has been modified to enhance the safety and efficacy of original (LAK) immunotherapy. This is a method of removing Natural Killer (NK) cells from the patient's own blood, culturing and amplifying the NK cells, increasing their ability to specifically attack cancer, and returning them for treatment. It is generally effective against all cancers. Experienced a case in which ANK therapy was remarkably effective against ATL, prostate cancer, and breast cancer. Treatment of ATL is basically chemotherapy, but it is not effective and has many side effects. Chemotherapy is also the main treatment for solid cancer patients whose condition has progressed in the same way, and the elderly, renal failure, and heart failure patients cannot be treated. ANK therapy is highly effective in ATL cases and is also very effective in certain solid tumor cases... Read More»
    DOI: 10.37421/2165-7831.2022.12.290

    Abstract HTML PDF

Google Scholar citation report
Citations: 443

Journal of Blood & Lymph received 443 citations as per Google Scholar report

Journal of Blood & Lymph peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward